Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Poster Presentation
© 2024 American Society of Hematology. All rights reserved.
Meeting: 2024 ASH® Annual Meeting
Indication: Follicular Lymphoma (FL)
Presenter: Catherine Thieblemont, MD
Affiliation: Service Hémato-Oncologie, Hôpital Saint- Louis, Paris, France
Presentation Date: December 8, 2024
Abstract Number: 3034
Session: Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
Related content: Follicular Lymphoma (FL)
Poster Presentation
Abstract Number: 4398
Presenter: Daniel J. Landsburg, MD
Indication: Follicular Lymphoma (FL)
Date Presented: December 9, 2024

To access this content please accept the following declarations.

This content was selected by and is provided to you upon your unsolicited request courtesy of Novartis with permission of ASH®.